

3 March 2017

Company Announcements Office Australian Securities Exchange

#### **NEW ISSUE OF SECURITIES - CLEANSING NOTICE AND APPENDIX 3B**

Aurora Labs Limited (**Company**) has today issued the following securities (**Securities**) to be quoted on ASX:

- 1. 2,800,000 ordinary fully paid shares (**Shares**) at an issue price of \$2.50 per Share to raise \$7 million (before costs) pursuant to a Placement to sophisticated and institutional investors managed by Bell Potter; and
- 2. 100,000 Shares issued on the exercise of 100,000 unlisted Options exercisable at \$0.20 (A3DAK)

The Company gives the following cleansing notice under section 708A(5)(e) of the Corporations Act 2001(Cth) (**Corporations Act**) that:

- 1. The Securities were issued without disclosure to investors under Part 6D.2 of the Corporations Act:
- 2. As at the date of this notice, the Company has complied with;
  - 2.1 the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - 2.2 section 674 of the Corporations Act; and
- 3. As at the date of this notice, there is no information to be disclosed which is 'excluded information', as defined in sections 708A(7) or 708A(8) of the Corporations Act.

An Appendix 3B new issue announcement in relation to the issue of the Securities by the Company is now attached.

Yours Sincerely

**AURORA LABS LIMITED** 

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name	of entity	
Auro	ra Labs Limited	
ABN		
	01.164.505	
44 00	01 164 505	
We (	the entity) give ASX the following	g information.
Dari	t 1 - All issues	
	nust complete the relevant sections (attach	n sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares (Shares)
	L	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	2,900,000 Shares
	_	
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Same as existing A3D Shares

01/08/2012 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

Do the \*securities rank equally 4 in all respects from the date of allotment with an existing +class of quoted \*securities?

> If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Issue price or consideration 5

- 2,800,000 Shares at \$2.50 per Share
- 100,000 Shares at \$0.20 per Share

Yes, same as existing A<sub>3</sub>D Shares

- Purpose of the issue 6 (If issued as consideration for the acquisition of assets, clearly identify those assets)
- Cash raised pursuant to Placement to institutions and sophisticated investors as announced on 24/2/2017.
- 2. Shares issued on exercise of 100,000 Unlisted Options Exercisable at \$0.20 Expiring 31/12/2018 (A3DAK).

Is the entity an +eligible entity 6a that has obtained security holder approval under rule 7.1A?

> If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

- 6b The date the security holder resolution under rule 7.1A was passed
- 6c under rule 7.1

Yes

28 November 2016

Number of \*securities issued 2,800,000 Shares without security holder approval

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Number of *securities issued with security holder approval under rule 7.1A	N/A	
Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
Number of securities issued under an exception in rule 7.2	100,000 Shares	
If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	LR 7.1: 5,450,000 LR 7.1A: 5,500,000	
Dates of entering *securities into uncertificated holdings or despatch of certificates	3 March 2017	
	Number	+Class
Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	25,639,304	Ordinary Shares
	with security holder approval under rule 7.1A  Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)  Number of securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.  If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements  Dates of entering *securities into uncertificated holdings or despatch of certificates  Number and *class of all *securities quoted on ASX (including the securities in	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)  Number of securities issued under rule 7.14, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A, and both values. Include the source of the VWAP calculation.  If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements  Dates of entering *securities into uncertificated holdings or despatch of certificates  Number  Number and *class of all *securities quoted on ASX (including the securities in N/A)  N/A  N/A  N/A  N/A  N/A  N/A  N/A

o1/08/2012 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)

Number	+Class
32,260,696	Ordinary Shares (restricted securities)
11,150,000	Unquoted Options Exercisable at \$0.20 Expiring 31/12/2018
225,000	Unquoted Options Exercisable at \$2.23 Expiring 30/11/2019
21,000,000	Performance Shares:

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

### Part 2 - Bonus issue or pro rata issue

11	Is security holder approval N/A required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the +securities will be offered	
14	+Class of +securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	

oı/o8/2012 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B	
New issue and	nouncement

30	How do *security holders sell their entitlements <i>in full</i> through a broker?			
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?			
32	How do *security holders dispose of their entitlements (except by sale through a broker)?			
33	<sup>+</sup> Despatch date			
	<b>3 - Quotation of securities</b> ed only complete this section if you are ap  Type of securities			
2 <del>1</del>	(tick one)			
(a)	Securities described in Part 1			
(b)	All other securities			
	Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities			
Entities that have ticked box 34(a) Additional securities forming a new class of securities				
Tick to docum	indicate you are providing the informatents	ion or		
35		securities, the names of the 20 largest holders of the he number and percentage of additional *securities		

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 100,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

oı/o8/2012 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

Entitie	es that have ticked box 34(b)		
38	Number of securities for which †quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another security, clearly identify that other security)		
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number	+Class

Appendix 3B Page 8 o1/08/2012

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 3/3/ 2017 (Company Secretary)

Print name: Mathew Whyte

== == == ==

01/08/2012 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	55,000,000	
<ul> <li>Add the following:</li> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	Nil	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
"A"	55,000,000	

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 10 01/08/2012

Step 2: Calculate 15% of "A"		
"B"		
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	8,250,000	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:		
Under an exception in rule 7.2		
• Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	Nil	
Step 4: Subtract "C" from ["A" x "Englacement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	8,250,000	
Note: number must be same as shown in Step 2		
Subtract "C"	2,800,000	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	5,450,000	
	[Note: this is the remaining placement capacity under rule 7.1]	

01/08/2012 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	Note: this value cannot be changed
Multiply "A" by 0.10	5,500,000
7.1A that has already been used  Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"E"	Nil

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	5,500,000
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	5,500,000
	Note: this is the remaining placement capacity under rule 7.1A

oı/o8/2012 Appendix 3B Page 13

<sup>+</sup> See chapter 19 for defined terms.